Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Short term Debt (2016 - 2026)

Usana Health Sciences (USNA) has disclosed Short term Debt for 6 consecutive years, with $23.0 million as the latest value for Q1 2025.

  • On a quarterly basis, Short term Debt rose 1642.42% to $23.0 million in Q1 2025 year-over-year; TTM through Mar 2025 was $23.0 million, a 1642.42% increase, with the full-year FY2024 number at $23.0 million, up 2826.21% from a year prior.
  • Short term Debt was $23.0 million for Q1 2025 at Usana Health Sciences, roughly flat from $23.0 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $23.0 million in Q4 2024 to a low of $786000.0 in Q4 2023.
  • A 4-year average of $11.6 million and a median of $10.0 million in 2022 define the central range for Short term Debt.
  • Peak YoY movement for Short term Debt: skyrocketed 2826.21% in 2024, then skyrocketed 1642.42% in 2025.
  • Usana Health Sciences' Short term Debt stood at $10.0 million in 2022, then tumbled by 92.14% to $786000.0 in 2023, then soared by 2826.21% to $23.0 million in 2024, then changed by 0.0% to $23.0 million in 2025.
  • Per Business Quant, the three most recent readings for USNA's Short term Debt are $23.0 million (Q1 2025), $23.0 million (Q4 2024), and $1.3 million (Q1 2024).